Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Longevity
Synthetic pineal tetrapeptide that activates telomerase and modulates melatonin production.
Peptide B
Longevity
Mitochondria-targeted tetrapeptide that restores bioenergetics by stabilizing cardiolipin.
Typical vial
10 mg
Typical dose
5000-10000 mcg
Half-life
~30 minutes (short half-life but biological effects persist due to gene expression changes)
FDA status
Not FDA approved for human use. No clinical trials submitted…
Typical vial
5 mg
Typical dose
5000-50000 mcg
Half-life
~4 hours
FDA status
Not FDA approved. FDA declined approval for Barth syndrome i…
Epithalon effects
SS-31 (Elamipretide) effects
Epithalon side effects
SS-31 (Elamipretide) side effects
Epithalon dosing ranges
Anti-aging and telomere support
5-10 mg · Once daily (SubQ) · 10-20 days, repeated 1-2 times per year
SS-31 (Elamipretide) dosing ranges
Mitochondrial support and longevity
5-50 mg · Once daily (SubQ) · 4-12 weeks
Epithalon: Synthetic pineal tetrapeptide that activates telomerase and modulates melatonin production. Typical dose 5000-10000 mcg. SS-31 (Elamipretide): Mitochondria-targeted tetrapeptide that restores bioenergetics by stabilizing cardiolipin. Typical dose 5000-50000 mcg. Both fall under the Longevity category.
Stacking Epithalon with SS-31 (Elamipretide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
Epithalon is typically dosed: Once daily (SubQ) for Anti-aging and telomere support. SS-31 (Elamipretide) is typically dosed: Once daily (SubQ) for Mitochondrial support and longevity.
Epithalon: Not FDA approved for human use. No clinical trials submitted to the FDA. SS-31 (Elamipretide): Not FDA approved. FDA declined approval for Barth syndrome in 2023, requesting additional efficacy data. Multiple clinical trials ongoing for other mitochondrial indications.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free